Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Michelle G. Rogers
Observed names:
Michelle G Rogers,
Michelle Rogers
Institution:
Mayo Clinic
Observed institution:
Mayo Clinic
OpenAlex ID:
A5104297988
Improved survival with daratumumab-CyBorD compared with CyBorD as frontline therapy for AL amyloidosis
2025
·
Binoy Yohannan
, Matthew Rees
, et al.
·
Blood Neoplasia
·
19
Venetoclax-based treatment combinations in relapsed/refractory multiple myeloma: practice patterns and impact of secondary cytogenetic abnormalities on outcomes
2025
·
Abiola Bolarinwa
, Madhu Nagaraj
, et al.
·
Blood Cancer Journal
·
11
PDF
Clonal plasma cell proportion in the synthetic phase identifies a unique high-risk cohort in multiple myeloma
2025
·
Saurabh Zanwar
, Dragan Jevremovic
, et al.
·
Blood Cancer Journal
·
11
PDF
Clinical Characteristics, Treatment Responses and Outcomes of Light Chain Multiple Myeloma
2025
·
Abiola Bolarinwa
, Saurabh Zanwar
, et al.
·
American Journal of Hematology
·
1
Impact of Serial Serum Free Light Chain Measurements on Response and Progression Assessments in Multiple Myeloma Patients with Measurable Disease
2024
·
Elham Askari
, Angela Dispenzieri
, et al.
·
Blood
·
1
Improved Survival with Daratumumab-Cybord Compared to Cybord As Frontline Therapy in Immunoglobulin Light Chain (AL) Amyloidosis
2024
·
Binoy Yohannan
, Matthew James Rees
, et al.
·
Blood
Exploring the utility of M-quant in the assessment of AL (immunoglobulin light chain) amyloidosis PA75 (#417)
2024
·
Angela Dispenzieri
, Jon Coker
, et al.
Quantitation of daratumumab among AL amyloidosis patients by M-quant measurement PA100 (#413)
2024
·
Angela Dispenzieri
, Jon Coker
, et al.
Show more works
View as search
Works count:
8
Citation count:
43
H-index:
3
I10-index:
3
Year
Topic
Type
